Form 4: DENTSPLY SIRONA Director Jonathan Mazelsky Acquires 13,880 Restricted Stock Units

DENTSPLY SIRONA Inc. Director Jonathan Jay Mazelsky reported the acquisition of 13,880 shares of common stock in the form of Restricted Stock Units, increasing his direct beneficial ownership to 27,812.453 shares.

Summary

• Jonathan Jay Mazelsky, a Director of DENTSPLY SIRONA Inc. (XRAY), acquired 13,880 shares of common stock on May 22, 2025.
• These shares were acquired as Restricted Stock Units (RSUs) at a price of $0 per share, indicating a grant as part of compensation.
• The RSUs are set to vest in full one year from the date of grant.
• Following this transaction, Mr. Mazelsky's direct beneficial ownership in DENTSPLY SIRONA Inc. increased to 27,812.453 shares.

Sentiment

Score: 7

Explanation: The acquisition of RSUs by a director is generally a positive signal, indicating alignment of interests and confidence in the company's future, though it's a routine compensation event rather than a direct investment.

Positives

• The acquisition of 13,880 Restricted Stock Units by Director Jonathan Jay Mazelsky demonstrates continued alignment of management interests with shareholder value, as RSUs typically incentivize long-term performance.
• The increase in Mr. Mazelsky's beneficial ownership reflects a deeper personal stake in the company's future success.

Negatives

• No specific negative information was disclosed in this Form 4 filing, as it primarily reports an insider stock acquisition.

Risks

• The value of the Restricted Stock Units (RSUs) is subject to the future performance of DENTSPLY SIRONA Inc.'s stock price, meaning the ultimate value realized by the director could be lower if the stock price declines.
• The vesting of RSUs one year from the grant date means the director's full ownership is contingent on continued employment and company performance over that period.

Future Outlook

The vesting schedule for the Restricted Stock Units indicates a future outlook tied to the company's performance over the next year, as the RSUs will vest in full one year from the grant date of May 22, 2025.

Management Comments

• No direct management comments or quotes were provided in this Form 4 filing, as it is a transactional report.

Industry Context

This Form 4 filing is a routine disclosure of insider stock ownership changes within the dental products and technology industry. Such grants of Restricted Stock Units are a common form of executive compensation designed to align management incentives with long-term shareholder value, consistent with practices across various industries.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to a director is a standard practice in executive compensation across publicly traded companies, including those in the healthcare and medical device sectors like DENTSPLY SIRONA.
• Companies such as Align Technology (ALGN) and Zimmer Biomet Holdings (ZBH) also frequently utilize RSU grants as part of their compensation packages for directors and executives to foster long-term commitment and performance alignment.
• The $0 acquisition price for RSUs is typical for equity grants that are part of a compensation plan, rather than a market purchase.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's interests with shareholders, as the value of the grant is tied to the company's stock performance.
• Employees: While not directly impacting all employees, such compensation structures for leadership can signal stability and long-term strategic focus.

Next Steps

• The Restricted Stock Units are scheduled to vest in full one year from the grant date of May 22, 2025.

Key Dates

Recommendation

Keywords

DENTSPLY SIRONA, XRAY, Form 4, Insider Trading, Restricted Stock Units, RSU, Stock Grant, Director, Beneficial Ownership, SEC Filing